The IL6ST Knockout A-549 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population engineered for the disruption of the IL6ST gene in the human A-549 lung carcinoma epithelial cell line. This product provides a heterogeneous pool of cells harboring targeted gene disruptions, enabling loss-of-function analysis of the glycoprotein 130 (gp130) signal transducer. The polyclonal format retains population-level diversity while abrogating IL6ST expression, offering a versatile model for investigating gp130-dependent signaling mechanisms without the clonal selection bottlenecks.
The host A-549 cell line is derived from the lung adenocarcinoma of a 58-year-old male and serves as a widely used model of type II alveolar epithelial cells. These adherent epithelial cells exhibit characteristics of human pulmonary adenocarcinoma, including expression of surfactant proteins and epithelial markers. The A-549 background is particularly relevant for studying non-small cell lung cancer biology, inflammatory responses, and therapeutic resistance, making it an ideal platform for dissecting the role of IL6ST in oncogenic signaling and cytokine-driven pathologies.
IL6ST encodes gp130, the common signal-transducing receptor subunit for the interleukin-6 (IL-6) cytokine family, which includes IL-6, leukemia inhibitory factor (LIF), ciliary neurotrophic factor (CNTF), oncostatin M (OSM), IL-11, IL-27, and cardiotrophin-1 (CTF1). Upon ligand binding to cognate alpha receptors (e.g., IL6R, LIFR, OSMR), gp130 homodimerizes or heterodimerizes, leading to activation of associated Janus kinases JAK1, JAK2, and TYK2. These kinases phosphorylate tyrosine residues within the cytoplasmic domain of gp130, creating docking sites for SH2 domain-containing proteins such as STAT3, STAT1, and the tyrosine phosphatase SHP2. SHP2 subsequently links to the GRB2-SOS-RAS axis to activate the MAPK/ERK pathway, while also contributing to PI3K-AKT signaling. STAT3 homodimers and heterodimers translocate to the nucleus to promote transcription of target genes including SOCS3, c-Myc, and other inflammatory and proliferative mediators. This knockout model thus eliminates a critical node for JAK/STAT, MAPK/ERK, and PI3K/AKT pathway crosstalk.
In the A-549 lung adenocarcinoma context, IL6ST-mediated signaling is implicated in tumor cell proliferation, survival, epithelial-mesenchymal transition, and chemoresistance. Autocrine and paracrine IL-6 production by lung cancer cells and the surrounding microenvironment activates gp130, driving STAT3 phosphorylation and downstream oncogenic programs. Disruption of IL6ST in this cell model allows researchers to dissect cytokine-dependent tumorigenic mechanisms, evaluate the contribution of gp130 to inflammatory carcinogenesis, and assess the potential of JAK/STAT inhibitors in treating IL-6-addicted lung cancers. Moreover, this knockout system provides a controlled background for reintroducing wild-type or mutant gp130 variants to study structure-function relationships and disease-associated polymorphisms.
Typical applications of the IL6ST Knockout A-549 Polyclonal Cells include interrogating IL-6-induced JAK/STAT3 signaling by Western blotting for phospho-STAT3 and RT-qPCR for SOCS3 and c-Myc expression, monitoring cell proliferation and migration in response to cytokine stimulation, and evaluating the efficacy of JAK inhibitors such as ruxolitinib. The cells are also suitable for reporter-based assays, flow cytometric detection of surface gp130 loss, and ELISA-based quantification of secreted IL-6 levels post-stimulation. For viral infection studies, the knockout background can be used to assess gp130 dependency in cytokine storm syndromes. For additional technical specifications and ordering information, please contact Ascent Research.
